ResMed (RMD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Nov, 2026Executive summary
FY26 revenue rose 10% to $5.7B (8% in constant currency); non-GAAP diluted EPS grew 17%, free cash flow exceeded $1.6B, and capital returned exceeded $1B, up 72% YoY.
FY27 priorities: enhance and transform the core business and build for the future; expected share repurchases of ~$1.5B and total stockholder returns above $1.85B, including a 10% quarterly dividend increase to $0.66 per share.
Completed the $340M gross-price Noctrix Health acquisition, adding restless legs syndrome treatment; MatrixCare divestiture closed September 1, 2026, with proceeds primarily directed to an accelerated share repurchase.
Voting matters and shareholder proposals
Annual meeting scheduled virtually for November 18, 2026 (US) / November 19, 2026 (Australia); stockholders vote on 10 directors, PwC auditor ratification for FY27, and an advisory say-on-pay proposal; board recommends FOR all.
Each director nominee and Proposals 2 and 3 require a majority of votes cast; broker non-votes do not affect director or say-on-pay outcomes, while brokers may vote on auditor ratification.
2025 say-on-pay received ~90% support, up from ~84% in 2024; the next annual advisory vote is scheduled for 2027.
Board of directors and corporate governance
Ten nominees stand for one-year terms; Ron Taylor retires after over 21 years, Carol Burt becomes lead director November 15, 2026, and board size decreases from 11 to 10 after the annual meeting.
Eight of 10 nominees are independent; independent directors meet in executive session at each board meeting, and all four standing committees have independent members and chairs.
FY26 board attendance was at least 75% for every director; the board conducts annual self-assessments, reviews strategy, and oversees CEO and executive succession planning, including an emergency plan.
CFO Brett Sandercock stepped down May 4, 2026; Aaron Bloomer succeeded him, with Sandercock serving as special advisor through December 2026 and as a consultant during 2027.
Latest events from ResMed
- Board backs all 10 director nominees, auditor ratification, and advisory say-on-pay approval.RMD
Proxy filing - Revenue rose 7% core CC, EPS 14%, and shareholder returns topped $1.0B.RMD
Q1 2027 - Shareholders were asked to elect 10 directors, ratify KPMG, and approve executive pay.RMD
Proxy Filing - Ten director elections, KPMG ratification, and advisory votes anchor the ballot.RMD
Proxy Filing - Board backs all three proposals: elect 11 directors, ratify KPMG and approve say-on-pay.RMD
Proxy Filing - Board backs all agenda items, including 11 director nominees and two employee plan amendments.RMD
Proxy Filing - 2026 saw strong growth, strategic investments, and enhanced sustainability and governance.RMD
Stewardship presentation - FY26 saw 8% revenue growth, 16% EPS growth, and $1B returned to shareholders.RMD
Corporate presentation - Volume-driven growth, digital engagement, and portfolio shifts drive robust outlook.RMD
Morgan Stanley 24th Annual Global Healthcare Conference